López BVM, Chacón QMM, Brealey MAM

Language: Spanish
References: 28
Page:
PDF size: 166.99 Kb.

ABSTRACT

Colorectal cancer (CRC) is a public health issue. It ranks as the third most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. Thus, prevention and early detection remain key strategies for reducing its incidence andmortality. In this regard, aspirin, or acetylsalicylic acid, has been studied as a chemopreventive agent, with its use being controversial. Actions both dependent and independent of COX-2 have been proposed, as well as direct effects on CRC cells and indirect effects on the tumor microenvironment. The evidence linking aspirin use to a lower incidence of CRC is substantial and has led to the recommendation of low-dose aspirin for reducing CRC incidence and mortality in a select group of patients. Furthermore, its use should not replace screening or other preventive measures. This review aims to synthesize the available literature regarding the antitumor mechanisms of aspirin and relevant clinical aspects such as age of initiation, duration, recommended dosage, and safety.

REFERENCES

1. Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett. 2023;10(1):451. Available from: https://scholar.google.com/scholar?q=urn:nbn:sciencein.cbl.2023.v10.451

2. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233-254. DOI: https://doi.org/10.3322/caac.21772

3. Fu Q, Liao H, Li Z, Chen X, Zhang X, Di J. Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis. Arch Med Sci. 2023;19(5):1428-1445. DOI: https://doi.org/10.5114/aoms/167480.

4. Grancher A, Michel P, Di Fiore F, Sefrioui D. Colorectal cancer chemoprevention: is aspirin still in the game? Cancer Biol Ther. 2022;23(1):446-461. DOI: https://doi.org/10.1080/15384047.2022.2104561

5. Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an update meta-analysis through 2019. Ann Oncol. 2020;31(5):558-568. DOI: https://doi.org/10.1016/j.annonc.2020.02.012.

6. Ghaddaf AA, Aziz M, Alomari MS, Abdulhamid AS, Alharbi FA, Mullah AN, Zaidi SF. Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. Int J Colorectal Dis. 2021;36:1711-1722. DOI: https://doi.org/10.1007/s00384-021-03880-3.

7. Wang L, Zhang R, Yu L, Xiao J, Zhou X, Li X, Song P, Li X. Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials. Front Oncol. 2021;11:690219. DOI: https://doi.org/10.3389/fonc.2021.690219

8. Hoskin AJ, Holt AK, Legge DN, Collard TJ, Williams AC, Vincent EE. Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer. Explor Target Antitumor Ther. 2023;4:600–615. DOI: https://doi.org/10.37349/etat.2023.00155.

9. Liang PS, Shaukat A, Crockett SD. AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review. Clinical Gastroenterology and Hepatology. 2021;19(7):1327-1336. DOI: https://doi.org/10.1016/j.cgh.2021.02.014

10. Onwuka SR, Boyd L, Wijesuriya R, Broun K, Marker J, Shub M, McIntosh JG, Macrae F, Chondros P, Saya S, Novy K, Jenkins MA, Walter FM, Trevena L, Martinez Gutierrez J, Fishman G, Emery J. Should I Take Aspirin? (SITA): RCT of a decision aid for cancer chemoprevention. Br J Gen Pract. 2024;BJGP.2023.0385. DOI: https://doi.org/10.3399/BJGP.2023.0385

11. Ma S, Han T, Sun C, Cheng C, Zhang H, Qu G, Bhan C, Yang H, Guo Z, Yan Y, Cao C, Ji Z, Zhou Q. Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. Int J Colorectal Dis. 2021;36:1653-1666. DOI: https://doi.org/10.1007/s00384-021-03889-8

12. Elwood PC, Morgan G, Delon C, Protty M, Galante J, Pickering J, Watkins J, Weightman A, Morris D. Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancer. 2021;15:1258. DOI: https://doi.org/10.3332/ecancer.2021.1258

13. Nafisi S, Støer NC, Veirød MB, Randel KR, Hoff G, Löfling L, Bosetti C, Botteri E. Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence from a Nationwide Registry-Based Cohort in Norway. Am J Gastroenterol. 2024;00:1-10. DOI: https://doi.org/10.14309/ajg.0000000000002695

14. Katona BW, Weiss JM. Chemoprevention of Colorectal Cancer. Gastroenterology. 2020;158(2):368-388. DOI: https://doi.org/10.1053/j.gastro.2019.06.047

15. Belayneh YM, Amare GG, Meharie BG. Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review. J Oncol Pharm Practice. 2021;0(0):1-8. DOI: http://dx.doi.org/10.1177/1078155220984846

16. Kolawole OR, Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022;23:1432. DOI: https://doi.org/10.3390/ijms23031432

17. Sankaranarayanan R, Kumar DR, Altinoz MA, Bhat GJ. Mechanisms of Colorectal Cancer Prevention by Aspirin—A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways. Int J Mol Sci. 2020;21:9018. DOI: http://dx.doi.org/10.3390/ijms21239018

18. Shaukat A, Kahi C, Burke C, Rabeneck L, Sauer B, Rex D. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. The American Journal of Gastroenterology. 2021;116(3):458-479. DOI: 10.14309/ajg.0000000000001122

19. Guo CG, Ma W, Drew DA. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021;7(3):428-435. DOI: 10.1001/jamaoncol.2020.7338

20. Perisetti A, Goyal H, Tharian B, Inamdar S, Mehta JL. Aspirin for prevention of colorectal cancer in the elderly: friend or foe? Ann Gastroenterol. 2021;34(1):1-11. DOI: https://doi.org/10.20524%2Faog.2020.0556

21. Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); Apr, 2022. (Evidence Synthesis, No. 211). Available from: https://www.ncbi.nlm.nih.gov/books/NBK580192/

22. Drew DA, Chan AT. Aspirin in the Prevention of Colorectal Neoplasia. Annu Rev Med. 2021;72:415-430. DOI: https://doi.org/10.1146%2Fannurev-med-060319-120913

23. Shami JJ, Zhao J, Pathadka S, Fai WE, Blais JE, Vora P, Soriano GM, Cheung KS, Leung WK, Wong IC, Chan EW. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022;12:e050510. DOI: 10.1136/bmjopen-2021-050510

24. Lin HD, Vora P, Soriano-Gabarró M, Chan KA. Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan. JAMA Netw Open. 2020;3(11):e2026494. DOI: 10.1001/jamanetworkopen.2020.26494.

25. Sada O, Ahmed K, Jeldo A, Shafi M. Role of Anti-inflammatory Drugs in the Colorectal Cancer. Hospital Pharmacy. 2020;55(3):169-181. DOI: https://doi.org/10.1177/0018578718823736

26. Hamoya T, Tomono S, Miyamoto, Fujii G, Wakabayashi K, Mutoh M. Theoretical basis validation and oxidative stress markers for cancer prevention clinical trials of aspirin. Sci Rep. 2023;13:21883. DOI: https://doi.org/10.1038%2Fs41598-023-49254-3

27. Barber LE, Bertrand KA, Sheehy S, White LF, Roy HK, Rosenberg L, Palmer JR, Petrick JL. Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and occurrence of colorectal adenoma in Black American women. Int J Cancer. 2023;153(12):1978-1987. DOI: https://doi.org/10.1002/ijc.34674

28. Lei J, Zhou Z, Fang J, Sun Z, He M, He B, Chen Q, Paek C, Chen P, Zhou J, Wang H, Tang M, Yin L, Chen Y. Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer. International Immunopharmacology. 2023;121:110350. DOI: https://doi.org/10.1016/j.intimp.2023.110350